Heart failure
Boehringer Ingelheim Leverages Late-Stage Pipeline for 25 New Launches over the Next Decade
Boehringer Ingelheim, Late-stage pipeline, 25 new launches, Decade, Jardiance, Heart failure approvals, Ofev, Pipeline expansion, Management reshuffle
Novo Nordisk Acquires Mid-Stage Heart Failure Biotech Cardior for Up to $1.1 Billion
Novo Nordisk, Cardior Pharmaceuticals, Heart Failure Biotech, Acquisition, $1.1 billion